drugset / Trial / NCT06679153

A Phase 2 Study of VVN461 Ophthalmic Solution for Noninfectious Anterior Uveitis

NCT06679153

Phase 2 Completed 89 enrolled VivaVision Biotech, Inc
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a multicenter, double-masked, randomized, active-controlled, parallel-comparison study conducted at sites in the China in subjects with Noninfectious Anterior Uveitis

Timeline

Start
2023-11-27
Primary completion
2024-12-29
Completion
2024-12-29

Drugs

EvaluationDrugModalityDoseRoute
Comparator Prednisolone Other / unclassified 1 % Other
Subject VVN461 Unknown 1 % Other

Indications